Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | FABP7 | O15540 | 2/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135377 | 0.89 | FABP5 (0.39) | FABP5EPHX2KMT2ATSHRHTT | |
| SCHEMBL9225108 | 0.77 | GAA (0.49) | FABP5EPHX2KMT2AMEN1HTT | |
| SCHEMBL9225114 | 0.76 | FABP5 (0.44) | FABP5EPHX2KMT2AMEN1FABP7 | |
| SCHEMBL29400602 | 0.75 | FABP5 (0.39) | FABP5KMT2ATSHRMEN1HTT | |
| SCHEMBL27575610 | 0.75 | FABP5 (0.46) | FABP5EPHX2KMT2ATSHRMEN1 | |
| SCHEMBL27143076 | 0.74 | FABP5 (0.52) | FABP5EPHX2KMT2AFABP7 | |
| SCHEMBL15119354 | 0.74 | KMT2A (0.60) | FABP5EPHX2KMT2AFABP7 | |
| SCHEMBL5188476 | 0.73 | RAB9A (0.40) | KMT2ATSHRMEN1HTTGAA | |
| SCHEMBL44676 | 0.73 | KMT2A (0.58) | FABP5EPHX2KMT2AFABP7 | |
| SCHEMBL14099780 | 0.73 | CYP1A2 (0.47) | FABP5EPHX2KMT2AFABP7GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110945017-B | Bifunctional compounds | 诺和诺德股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240000803-A1 | ORAL FORMULATION OF BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO | D&D PHARMATECH INC. (KR) | 2024-01-04 | — | — | US | disclosed |
| CN-116940384-A | Oral formulations having bioactive material conjugates coupled to biotin moieties, fatty acid moieties, or combinations thereof | D&D制药技术股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116916965-A | Bioactive material conjugates with conjugated biotin moieties, fatty acid moieties, or combinations thereof | D&D制药技术股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4252780-A1 | BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO | D&D Pharmatech Inc. (KR) | 2023-10-04 | — | — | EP | disclosed |
| EP-4252781-A1 | ORAL FORMULATION OF BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO | D&D Pharmatech Inc. (KR) | 2023-10-04 | — | — | EP | disclosed |
| US-11572398-B2 | GLP-1 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2023-02-07 | — | — | US | disclosed |
| US-20230000834-A1 | PHYSIOLOGICALLY ACTIVE SUBSTANCE BOUND TO BIOTIN MOIETY, AND COMPOSITION FOR ORAL ADMINISTRATION INCLUDING SAME | D&D PHARMATECH, INC. (KP) | 2023-01-05 | — | — | US | disclosed |
| US-11518795-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2022-12-06 | — | — | US | disclosed |
| CN-108699126-B | GLP-1 derivatives and uses thereof | 诺和诺德股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| WO-2006097537-A2 | ACYLATED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097538-A1 | EXTENDED GLP-1 COMPOUNDS | NOVO NORDISK A/S (DK) | 2006-09-21 | — | — | WO | disclosed |
| EP-1434599-A4 | HUMAN 3 RELAXIN | FLOREY HOWARD INST (AU) | 2006-09-20 | — | — | EP | disclosed |
| US-20060135434-A1 | New peptides | GE HEALTHCARE AS (NO) | 2006-06-22 | — | — | US | disclosed |
| US-20060089307-A1 | Peptides that bind to the heparin binding domian of vegf and vegfr-2 | GE HEALTHCARE AS (NO) | 2006-04-27 | — | — | US | disclosed |
| EP-1578785-A1 | PEPTIDES THAT BIND TO THE HEPARIN BINDING DOMAIN OF VEGF AND VEGFR-2 | Amersham Health AS (NO) | 2005-09-28 | — | — | EP | disclosed |
| US-20050026822-A1 | Human 3 relaxin | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
| WO-2004058802-A1 | PEPTIDES THAT BIND TO THE HEPARIN BINDING DOMIAN OF VEGF AND VEGFR-2 | AMERSHAM HEALTH AS (NO) | 2004-07-15 | — | — | WO | disclosed |
| EP-1434599-A1 | HUMAN 3 RELAXIN | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003030930-A1 | HUMAN 3 RELAXIN | HOWARD FLOREY INSTITUTE OF EXPERIMENTAL PHYSIOLOGY AND MEDICINE (AU) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135434-A1 | New peptides | FLT4, FLT1, KDR | FABP5 734/4885EPHX2 3704/4885KMT2A 4457/4885 |
| US-20240000803-A1 | ORAL FORMULATION OF BIOLOGICALLY ACTIVE MATERIAL CONJUGATE HAVING BIOTIN MOIETY, FATTY ACID MOIETY, OR COMBINATION THEREOF COUPLED THERETO | FABP2, FABP1, ALOX15B | FABP5 16/4885EPHX2 255/4885KMT2A 4144/4885 |
| US-20060089307-A1 | Peptides that bind to the heparin binding domian of vegf and vegfr-2 | KDR, FLT1, FLT4 | FABP5 439/4885EPHX2 3981/4885KMT2A 4553/4885 |
| US-20230000834-A1 | PHYSIOLOGICALLY ACTIVE SUBSTANCE BOUND TO BIOTIN MOIETY, AND COMPOSITION FOR ORAL ADMINISTRATION INCLUDING SAME | BTD, FABP2, PLPBP | FABP5 62/4885EPHX2 719/4885KMT2A 3868/4885 |
| US-11572398-B2 | GLP-1 derivatives and uses thereof | GLP1R, GIPR, GCG | FABP5 382/4885EPHX2 1828/4885KMT2A 4053/4885 |
| US-11518795-B2 | Double-acylated GLP-1 derivatives | GLP1R, GIPR, GPR119 | FABP5 944/4885EPHX2 1351/4885KMT2A 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.